Peptides Similar to Nemifitide
Compare Nemifitide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semax: Moderate - Both are short peptides with CNS activity and mood-related research applications
- •Selank: Moderate - Both are short peptides targeting mood-related pathways with clinical trial data
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Nemifitide (current) | - | - |
| Semax | Moderate - Both are short peptides with CNS activity and mood-related research applications | Nemifitide is an MIF-1 analog targeting 5-HT2A receptors for antidepressant effects, while semax is an ACTH analog modulating BDNF for nootropic effects. Semax is approved in Russia. |
| Selank | Moderate - Both are short peptides targeting mood-related pathways with clinical trial data | Nemifitide targets 5-HT2A receptors for depression while selank is a tuftsin analog modulating GABA for anxiety. Different indications within mood disorders. |
| PE-22-28 | Moderate - Both are peptides with antidepressant properties and neurogenesis effects in preclinical models | Nemifitide targets 5-HT2A receptors and has phase 3 clinical data, while PE-22-28 blocks TREK-1 potassium channels with only preclinical data from a single laboratory. |
SemaxModerate - Both are short peptides with CNS activity and mood-related research applications
Differences
Nemifitide is an MIF-1 analog targeting 5-HT2A receptors for antidepressant effects, while semax is an ACTH analog modulating BDNF for nootropic effects. Semax is approved in Russia.
Advantages
Clinical approval in Russia, intranasal administration, nootropic and neuroprotective properties, decades of use
Disadvantages
Different mechanism, primarily nootropic rather than antidepressant, not specifically developed for depression
SelankModerate - Both are short peptides targeting mood-related pathways with clinical trial data
Differences
Nemifitide targets 5-HT2A receptors for depression while selank is a tuftsin analog modulating GABA for anxiety. Different indications within mood disorders.
Advantages
Clinical approval in Russia, anxiolytic indication, immune modulation, intranasal delivery
Disadvantages
Primarily anxiolytic rather than antidepressant, different target receptor systems
PE-22-28Moderate - Both are peptides with antidepressant properties and neurogenesis effects in preclinical models
Differences
Nemifitide targets 5-HT2A receptors and has phase 3 clinical data, while PE-22-28 blocks TREK-1 potassium channels with only preclinical data from a single laboratory.
Advantages
Defined ion channel target, extremely high potency (IC50 0.12 nM), rapid neurogenesis induction
Disadvantages
Preclinical only, single research group, no human safety data, unknown clinical translatability
Peptides Related to Nemifitide#
Nemifitide is distinguished by its status as one of the most clinically advanced peptide antidepressants, with data from over 12 clinical trials. Its MIF-1 analog structure and 5-HT2A mechanism place it in a unique category among neuropeptides. The following comparisons examine peptides with related CNS applications.
Semax#
Semax is an ACTH(4-10) analog approved in Russia for cognitive enhancement and stroke recovery. While both are short peptides with CNS applications, semax is primarily nootropic while nemifitide is specifically antidepressant. Semax modulates BDNF expression rather than serotonin receptors. Semax has the advantage of clinical approval and intranasal delivery.
Selank#
Selank is a tuftsin analog approved in Russia for anxiety disorders. Both target mood-related conditions but through different mechanisms and for different indications. Nemifitide targets depression via 5-HT2A modulation while selank targets anxiety via GABAergic modulation. Selank has clinical approval and a non-invasive intranasal route.
PE-22-28#
PE-22-28 is a spadin analog that blocks TREK-1 potassium channels with potent antidepressant effects in mouse models. Both are peptide antidepressants but nemifitide is far more clinically advanced, with human trial data from hundreds of subjects, while PE-22-28 remains preclinical with data from a single lab.
Summary Comparison#
| Feature | Nemifitide | Semax | Selank | PE-22-28 |
|---|---|---|---|---|
| Mechanism | 5-HT2A modulation | BDNF / ACTH analog | Tuftsin / GABA | TREK-1 blockade |
| Primary indication | Depression | Cognitive/stroke | Anxiety | Depression |
| Clinical status | Phase 3 | Approved (Russia) | Approved (Russia) | Preclinical |
| Route | Subcutaneous | Intranasal | Intranasal | Intraperitoneal (research) |
| Key advantage | Human trial data | Clinical approval | Anxiolytic approval | Potent target |
Comparison Context#
Nemifitide belongs to the Neuropeptide category of research peptides. Comparing Nemifitide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Nemifitide in mechanism, indication, or therapeutic category:
Nemifitide vs Semax#
Similarity: Moderate - Both are short peptides with CNS activity and mood-related research applications
Key Differences: Nemifitide is an MIF-1 analog targeting 5-HT2A receptors for antidepressant effects, while semax is an ACTH analog modulating BDNF for nootropic effects. Semax is approved in Russia.
Advantages of Semax: Clinical approval in Russia, intranasal administration, nootropic and neuroprotective properties, decades of use
Disadvantages of Semax: Different mechanism, primarily nootropic rather than antidepressant, not specifically developed for depression
Researchers choosing between Nemifitide and Semax should consider the development stage, available evidence, and specific research objectives when making their selection.
Nemifitide vs Selank#
Similarity: Moderate - Both are short peptides targeting mood-related pathways with clinical trial data
Key Differences: Nemifitide targets 5-HT2A receptors for depression while selank is a tuftsin analog modulating GABA for anxiety. Different indications within mood disorders.
Advantages of Selank: Clinical approval in Russia, anxiolytic indication, immune modulation, intranasal delivery
Disadvantages of Selank: Primarily anxiolytic rather than antidepressant, different target receptor systems
Researchers choosing between Nemifitide and Selank should consider the development stage, available evidence, and specific research objectives when making their selection.
Nemifitide vs PE-22-28#
Similarity: Moderate - Both are peptides with antidepressant properties and neurogenesis effects in preclinical models
Key Differences: Nemifitide targets 5-HT2A receptors and has phase 3 clinical data, while PE-22-28 blocks TREK-1 potassium channels with only preclinical data from a single laboratory.
Advantages of PE-22-28: Defined ion channel target, extremely high potency (IC50 0.12 nM), rapid neurogenesis induction
Disadvantages of PE-22-28: Preclinical only, single research group, no human safety data, unknown clinical translatability
Researchers choosing between Nemifitide and PE-22-28 should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Nemifitide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer